In case you missed it, the Campaign for Sustainable Rx Pricing (CSRxP) recently
released an analysis examining how the ten largest pharmaceutical companies by
U.S. revenue allocate each dollar of their revenue.





 

September 11, 2026



TOPLINE



In case you missed it, the Campaign for Sustainable Rx Pricing (CSRxP) recently
released
<[link removed]>
an analysis examining how the ten largest pharmaceutical companies by U.S.
revenue allocate each dollar of their revenue.



Using U.S. Securities and Exchange Commission data for calendar year 2025,
CSRxP’s updated “Big Pharma Dollar
<[link removed]>
” analysis found that brand name pharmaceutical manufacturers spend three times
more on profits, advertising and corporate overhead than they invest in
research and development (R&D). More than 80 cents of every dollar in Big
Pharma revenue goes toward something other than researching and developing new
treatments.



Coverage of the analysis last week in POLITICO
<[link removed]>
noted, “Out of every dollar, the analysis found that the top 10 largest
brand-name pharmaceutical manufacturers spend 19 cents on advertising, selling,
general and administrative costs; 9 cents on corporate overhead; 18 cents on
research and development; 25 cents on production costs; and 4 cents on taxes.
The remaining 25 cents goes toward profits, which includes money spent on
shareholder dividends and stock buybacks, as well as profits banked by the
company.” Read more on the analysisHERE
<[link removed]>
andHERE
<[link removed]>
.



QUOTE OF THE WEEK



“Simply put: Generic medicines save money. Generics and biosimilars are the
only sector that consistently results in decreased spending across the U.S.
healthcare ecosystem.”



-John Murphy III, President and CEO of AAM
<[link removed]>



DATA POINTS YOU SHOULD KNOW



$25.4 Billion



The amount of savings generated from biosimilar drugs in 2025, according to a
report
<[link removed]>
from the Association of Accessible Medicines.



TWEETS OF THE WEEK



@P4ADNOW <[link removed]>: “Big Pharma
says high drug prices are necessary to fund innovation. The numbers tell a
different story. New analysis from the @RxPricing exposes that the 10 largest
brand-name pharmaceutical manufacturers spend more than 80 cents of every
dollar of revenue on something other than drug research and development.
Americans are paying the highest prescription drug prices in the world because
of the pharmaceutical industry. It’s time to stop accepting the status quo. If
you want to use your story with high cost prescription drugs to create policy
change, join our community today:
[link removed]
<[link removed]>”



@AccessibleMeds <[link removed]>
: “JUST RELEASED! The 2026 U.S. Generic & Biosimilar Medicines Savings Report
shows $3.6 TRILLION of savings in the last decade, positioning lower-cost
prescription options as a force of strength and security for the U.S.
healthcare ecosystem and the economy. Access the full report to learn how
Generic & Biosimilar Medicines are Driving America FORWARD!
[link removed]
<[link removed]>”



ROAD TO RECOVERY



The Daily Record: Big Pharma’s Patent Games Are Costing Patients. Congress
Must Act
<[link removed]>



As a physician pathologist, I have spent my career looking closely at what
lies beneath the surface. When we do the same with the high price of
prescription drugs, one culprit becomes impossible to ignore: Big Pharma’s
abuse of the patent system. Brand-name manufacturers set their product prices,
and patent abuse gives them the power to raise those prices while blocking
competition from more affordable alternatives… As president of MedChi, I
represent physicians across Maryland who want their patients to receive the
treatments they need. We value the scientists and companies responsible for
developing new cures and therapies. But respect for innovation does not require
silence when the patent system is exploited to keep affordable competitors off
the market… The patent system should serve innovation and the public good, not
become a tool for extending monopolies long after the original bargain has run
its course.



The Washington Examiner: It’s Time For Congress To End Big Pharma’s War On
Generics
<[link removed]>



Each day, millions of people pick up a prescription drug from their local
pharmacy or mailbox. Most are affordable, with co-pays on average less than $7
for 90% of drugs. But for a growing number of patients, and the employers,
unions, or programs such as Medicare that provide their drug coverage, the cost
of some life-saving brand drugs is staggering. The brand drug lobby tells us
these sky-high prices are a necessity of the remarkable innovation we enjoy in
healthcare. And make no mistake, that innovation is important. But as a growing
amount of research shows, for many drugs this is an illusion. The high prices
are part of Big Pharma’s masterclass in patent loopholes and legal maneuvering.
They are waging a war on generic drug competition and artificially keeping
prices too high for too long for too many.



The Pharma Letter: US Generic And Biosimilar Meds Save $496B In Just 1 Year
<[link removed]>



The US Association for Accessible Medicines and the Biosimilars Council today
released the 2026 US Generic & Biosimilar Medicines Savings Report - Forward
for America. AAM’s annual savings report highlights that generic and biosimilar
medicines created $496 billion in savings in 2025 for patients and the overall
healthcare system. Generics and biosimilars have saved over $3.6 trillion in
the last decade, the trade groups noted.



PHARMA’S POOR PROGNOSIS



STAT News: The Gifts From Pharma Companies That Keep On Giving
<[link removed]>



For years, drugmakers have offered free meals, samples, gifts, and speaking
fees to physicians, a widely studied issue due to concerns such largesse may
unduly influence prescribing habits. But to what extent have interactions
between doctors and pharmaceutical representatives changed behaviors over time?
A new analysis attempts to provide some answers. A group of researchers
surveyed 283 physicians who were among more than 1,300 medical students and
residents queried in 2011. They compared the responses to an updated effort
that was undertaken two years ago, and the results suggest the topic is likely
to remain contentious.



###





























Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>